| Kim, In K |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT05469022: Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy |
|
|
| Recruiting | 2 | 40 | RoW | Neoadjuvant lazertinib, Neoadjuvant LECLAZA | Konkuk University Medical Center, Yuhan Corporation | Non Small Cell Lung Cancer | 05/24 | 05/27 | | |
| Active, not recruiting | 2 | 256 | Europe, Canada, US, RoW | Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255 | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics | Locally Advanced or Metastatic Urothelial Carcinoma | 01/25 | 01/25 | | |
NCT04122833: Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study |
|
|
| Recruiting | N/A | 80 | RoW | Next generation sequencing | Konkuk University Medical Center, Roche Diagnostics, Foundation Medicine | Adenocarcinoma of Lung, EGFR Activating Mutation | 09/23 | 12/24 | | |
| Sticherling, Michael |
| Recruiting | 2/3 | 474 | Europe, Canada, Japan, US, RoW | Litifilimab, BIIB059, Placebo | Biogen, Biogen Idec Research Limited | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | 10/26 | 12/27 | | |
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis |
|
|
| Completed | 1 | 24 | Europe, US | CDX-0159, barzolvolimab, Normal saline | Celldex Therapeutics | Prurigo Nodularis | 07/23 | 07/23 | | |
|
| Cloven, Noelle G |
| Terminated | 3 | 20 | Canada, US, RoW | Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo | Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 09/23 | 09/23 | | |
| Recruiting | 3 | 220 | Europe, Canada, US, RoW | Selinexor, KPT-330, Matching Placebo for selinexor | Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group | Endometrial Cancer | 01/25 | 01/28 | | |
|
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 3 | 270 | Europe, Canada, US, RoW | avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex | Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group | Low Grade Serous Ovarian Cancer | 10/28 | 02/31 | | |
| Recruiting | 2/3 | 268 | Europe, Canada, US, RoW | Navtemadlin, KRT-232, Navtemadlin Placebo | Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Endometrial Cancer | 08/25 | 07/27 | | |
| Recruiting | 2 | 76 | Canada, US, RoW | ZN-c3, azenosertib, KP-2638 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Uterine Serous Carcinoma | 11/24 | 05/25 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
| Active, not recruiting | 2 | 58 | US | ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda | OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation | Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 06/25 | 06/26 | | |
| Active, not recruiting | 1/2 | 523 | US | upifitamab rilsodotin, XMT-1536, UpRi | Mersana Therapeutics | Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | 05/23 | 10/24 | | |
NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies |
|
|
| Recruiting | 1/2 | 60 | US | Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara | Onconova Therapeutics, Inc. | Endometrioid Endometrial Cancer | 01/26 | 02/26 | | |
| Recruiting | 1/2 | 390 | US | ACR-368, prexasertib, Gemcitabine, OncoSignature | Acrivon Therapeutics, GOG Foundation | Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma | 07/26 | 12/27 | | |
| Kim, Jae Weon |
NCT04655482: Treat-and-extend Using Aflibercept for Type 3 Neovascularization |
|
|
| Recruiting | 4 | 30 | RoW | Aflibercept Injection, Intravitreal injection of aflibercept (Eylea, Bayer co.) | Kim's Eye Hospital, Bayer | Retinal Angiomatous Proliferation | 12/23 | 08/24 | | |
NCT04840550: Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs |
|
|
| Recruiting | 3 | 390 | RoW | Lansoprazole 15 mg, Tegoprazan 25 mg | HK inno.N Corporation | Preventive Peptic Ulcer | 06/24 | 07/24 | | |
| Recruiting | 3 | 496 | RoW | Neu2000KWL group, Placebo group | GNT Pharma | Ischemic Stroke | 06/24 | 01/25 | | |
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
| Recruiting | 2 | 100 | US, RoW | VGT-309 | Vergent Bioscience, Inc. | Lung Cancer, Lung Metastases | 11/24 | 12/24 | | |
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 50 | RoW | EB-203 | EyebioKorea, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 08/25 | 01/26 | | |
NCT05933031: Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients |
|
|
| Recruiting | 2 | 381 | RoW | Tegoprazan 50 mg Triple Therapy, Tegoprazan 100 mg Triple Therapy, Lansoprazole Triple Therapy | HK inno.N Corporation | Helicobacter Pylori Infection | 12/24 | 12/24 | | |
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema |
|
|
| Recruiting | 2 | 150 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Diabetic Macular Edema (DME) | 11/25 | 12/25 | | |
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration |
|
|
| Recruiting | 2 | 180 | Japan, US, RoW | KHK4951, Aflibercept Injection | Kyowa Kirin Co., Ltd. | Neovascular Age-Related Macular Degeneration (nAMD) | 11/25 | 12/25 | | |
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy |
|
|
| Recruiting | 2 | 464 | Europe, RoW | Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo | Chiesi Farmaceutici S.p.A. | Uncontrolled Asthma | 12/25 | 12/25 | | |
NCT05509543: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T |
|
|
| Completed | 1 | 60 | RoW | IY-NT-T, IY-NT-R, Noltec(the brand name) | Il-Yang Pharm. Co., Ltd. | Pharmacokinetics | 10/22 | 12/23 | | |
NCT05729386: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions |
|
|
| Recruiting | 1 | 34 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT05703984: A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions |
|
|
| Recruiting | 1 | 50 | RoW | GC2129A(Period 1), Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1), GC2129A(Period 2), Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2) | GC Biopharma Corp | Healthy Volunteers | 04/23 | 04/23 | | |
NCT05617651: Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T |
|
|
| Not yet recruiting | 1 | 50 | RoW | IY-NT-T, IY-NT-R, Noltec(the brand name) | Il-Yang Pharm. Co., Ltd. | Pharmacokinetics | 12/24 | 12/25 | | |
NCT05525949: Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke |
|
|
| Completed | N/A | 93 | RoW | VIVID Brain, No-treatment Control | Nunaps Inc | Visual Fields Hemianopsia, Hemianopsia, Homonymous | 08/23 | 11/23 | | |
NCT06406439: DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients |
|
|
| Recruiting | N/A | 120 | RoW | Smart Insulin Pen, DIA:CONN P8 | G2e Co., Ltd | Diabetes Mellitus | 10/24 | 12/24 | | |
| Kim, Dong Soon |
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age |
|
|
| Recruiting | 4 | 50 | RoW | rMenB+OMV NZ | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Meningitis, Meningococcal | 04/26 | 09/26 | | |
ODYSSEY, NCT04373564: Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
|
|
| Recruiting | 4 | 2076 | Europe, Canada, US, RoW | Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Eovist, Primovist, BAY86-4873, Gadobenate dimeglumine, MultiHance, Gadodiamide, Omniscan, Gadoterate meglumine, Dotarem, Magnescope, Gadobutrol, BAY86-4875, Gadavist, Gadovist, Gadoteridol, ProHance | Guerbet, Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor) | Motor Function, Cognitive Function, Contrast Media | 12/28 | 12/28 | | |
| Active, not recruiting | 3 | 197 | RoW | besifovir 150mg, tenofovir 300mg | IlDong Pharmaceutical Co Ltd | Chronic Hepatitis B | 02/16 | 01/23 | | |
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years |
|
|
| Recruiting | 3 | 249 | RoW | DTaP-IPV combination vaccine | Boryung Biopharma Co., Ltd. | Diphtheria, Tetanus, Pertussis, Poliomyelitis | 12/20 | 07/21 | | |
| Active, not recruiting | 3 | 104 | RoW | Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery | Biosolution Co., Ltd. | Articular Cartilage Defect, Articular Cartilage Degeneration | 09/23 | 09/24 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT03459534: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs |
|
|
| Recruiting | 3 | 173 | RoW | Radotinib HCl, SUPECT | Il-Yang Pharm. Co., Ltd. | Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome | 06/26 | 12/27 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT05733624: Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis |
|
|
| Completed | 2 | 116 | RoW | SCAI-001 0.01% eyedrop, Cyclosporine 0.01%, SCAI-001 0.02% eyedrop, Cyclosporine 0.02%, Restasis 0.05% eyedrop, Cyclosporine 0.05% | SCAI Therapeutics | Dry Eye Syndromes | 08/23 | 02/24 | | |
EB-203-201, NCT06487039: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration |
|
|
| Recruiting | 2 | 50 | RoW | EB-203 | EyebioKorea, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 08/25 | 01/26 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 2 | 18 | Europe, US, RoW | HM15912 Active, Placebo | Hanmi Pharmaceutical Company Limited, Hanmi Pharm. Co., Ltd., Hanmi Pharmaceutical Co., Ltd. | Short Bowel Syndrome | 12/27 | 05/28 | | |
NCT04446351: Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 244 | Canada, Japan, US, RoW | GSK6097608, Dostarlimab, Cobolimab, Belrestotug, GSK4428859A, EOS884448 | GlaxoSmithKline, 23andMe, Inc., iTeos Therapeutics | Neoplasms | 09/25 | 09/25 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
| Recruiting | 1 | 180 | Europe, Canada, US, RoW | ELVN-001 | Enliven Therapeutics | Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml | 12/26 | 12/26 | | |
| Lee, Dong-Gun |
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study |
|
|
| Recruiting | 3 | 12000 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 09/26 | 09/26 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study |
|
|
| Recruiting | 3 | 274 | Europe, US, RoW | DAS181, Placebo, DAS181 COVID-19, DAS181 OL | Ansun Biopharma, Inc. | Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19 | 08/25 | 08/25 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
| Shahin, Mark |
| Terminated | 3 | 20 | Canada, US, RoW | Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo | Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) | High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 09/23 | 09/23 | | |
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer |
|
|
| Recruiting | 3 | 418 | Europe, Canada, US, RoW | Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab | AbbVie, GOG Foundation | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 03/27 | 04/29 | | |
| Completed | 2 | 150 | US, RoW | Paclitaxel, Afuresertib, LAE002 | Laekna Limited | Platinum-resistant Ovarian Cancer | 07/23 | 06/24 | | |
| Active, not recruiting | 2 | 53 | US | Abemaciclib, Letrozole | Gynecologic Oncology Group, Eli Lilly and Company | Endometrial Cancer | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 51 | US | Ribociclib, Letrozole | Gynecologic Oncology Group, Novartis | Low Grade Serous Carcinoma | 12/23 | 12/24 | | |
| Investigator, Prinicpal |
NCT05120895: An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia |
|
|
| Active, not recruiting | N/A | 3300 | RoW | Mevalotin | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Dyslipidemia | 04/25 | 04/25 | | |
| Kim, Inho |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT03671850: VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients |
|
|
| Recruiting | 2 | 48 | RoW | VT-EBV-N, Placebo | ViGenCell Inc. | Extranodal NK/T-cell Lymphoma | 12/23 | 06/24 | | |
NCT04189432: Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease |
|
|
| Active, not recruiting | 2 | 84 | RoW | SCM-CGH, Placebo | SCM Lifescience Co., LTD. | Chronic Graft-versus-host-disease | 03/24 | 09/24 | | |
| Active, not recruiting | 1 | 19 | RoW | AST-021p | Aston Sci. Inc. | Advanced Cancer | 08/23 | 11/23 | | |
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) |
|
|
| Completed | N/A | 191 | RoW | No Intervention | Takeda | Multiple Myeloma | 07/23 | 08/23 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
